CY1107323T1 - Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας - Google Patents
Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊαςInfo
- Publication number
- CY1107323T1 CY1107323T1 CY20071100174T CY071100174T CY1107323T1 CY 1107323 T1 CY1107323 T1 CY 1107323T1 CY 20071100174 T CY20071100174 T CY 20071100174T CY 071100174 T CY071100174 T CY 071100174T CY 1107323 T1 CY1107323 T1 CY 1107323T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hypothesis
- protective action
- hair
- hair disease
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
Abstract
Συνθέσεις που αναστέλλουν τη δράση του NF-κΒ ή τη δράση του πρωτεασώματος ή ευνοούν τον σχηματισμό οστών και την τριχοφυΐα και είναι κατά συνέπεια χρήσιμες στην θεραπεία της οστεοπόρωσης, της θραύσης ή ατέλειας των οστών, του πρωτογενούς ή δευτερογενούς υπερπαραθυροειδισμού, των περιοδοντικών ασθενειών ή ατελειών, της μεταστατικής ασθένειας των οστών, της οστεολυτικής ασθένειας των οστών, της μεταπλαστικής χειρουργικής, της μεταπροσθετικής χειρουργικής συνδέσμων, και της μετά οδοντικής εμφύτευσης. Επίσης διεγείρουν την παραγωγή τριχοθυλακίων και επομένως είναι χρήσιμες στην διέγερση τριχοφυΐας, συμπεριλαμβανομένης της πυκνότητας μαλλιών, σε οργανισμούς όπου αυτό είναι επιθυμητό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/113,947 US6462019B1 (en) | 1998-07-10 | 1998-07-10 | Inhibitors of proteasomal activity and production for stimulating bone growth |
EP99933827A EP1096924B1 (en) | 1998-07-10 | 1999-07-09 | Inhibitors of proteasomal activity for stimulating hair growth |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1107323T1 true CY1107323T1 (el) | 2012-11-21 |
Family
ID=22352464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20071100174T CY1107323T1 (el) | 1998-07-10 | 2007-02-09 | Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας |
Country Status (13)
Country | Link |
---|---|
US (3) | US6462019B1 (el) |
EP (1) | EP1096924B1 (el) |
JP (2) | JP2003522107A (el) |
AT (1) | ATE345785T1 (el) |
AU (1) | AU771297B2 (el) |
CA (1) | CA2337988C (el) |
CY (1) | CY1107323T1 (el) |
DE (1) | DE69934120T2 (el) |
DK (1) | DK1096924T3 (el) |
ES (1) | ES2273505T3 (el) |
HK (1) | HK1035870A1 (el) |
PT (1) | PT1096924E (el) |
WO (1) | WO2000002548A2 (el) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US7687462B2 (en) * | 1999-10-05 | 2010-03-30 | The Regents Of The University Of California | Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition |
US20090060988A1 (en) * | 1999-10-05 | 2009-03-05 | Kang Ting | Nell-1 enhanced bone mineralization |
US7052856B2 (en) * | 1999-10-05 | 2006-05-30 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
US7884066B2 (en) | 1999-10-05 | 2011-02-08 | The Regents Of The University Of California | NELL-1 enhanced bone mineralization |
EP1477180A1 (en) * | 1999-10-20 | 2004-11-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
WO2004103410A1 (en) | 2002-06-06 | 2004-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods compositions and articles of manufacture for modulating bone growth |
US7041309B2 (en) * | 2002-06-13 | 2006-05-09 | Neuropro Technologies, Inc. | Spinal fusion using an HMG-CoA reductase inhibitor |
EP1542682A4 (en) * | 2002-07-18 | 2007-10-31 | Univ Utah Res Found | NEW HEMMER OF UBIQUITINE ISOPEPTIDASES |
US7029006B2 (en) * | 2002-08-29 | 2006-04-18 | Canon Kabushiki Kaisha | Sheet feeding apparatus and image forming apparatus |
EP1551978A4 (en) * | 2002-09-13 | 2006-02-01 | Univ California | BY NELL-1 IMPROVED BONE MINERALIZATION |
EP1594889B1 (en) * | 2003-02-07 | 2011-04-06 | The Regents of The University of California | Nell peptide expression systems and bone formation activity of nell peptide |
US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
KR101138032B1 (ko) * | 2003-11-05 | 2012-04-20 | 오스테오스크린, 인코포레이티드 | 은행나무 플라바노이드에 의한 발모 자극 조성물 |
US7691607B2 (en) * | 2004-02-09 | 2010-04-06 | The Regents Of The University Of California | Expression system of NELL peptide |
PL1745064T3 (pl) | 2004-04-15 | 2011-06-30 | Onyx Therapeutics Inc | Związki do hamowania enzymu proteazomu |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) * | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CA2565407A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Compounds for enzyme inhibition |
AU2005243140A1 (en) * | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
FR2870739B1 (fr) * | 2004-05-26 | 2008-05-16 | Oreal | Utilisation du lif en cosmetique et en dermatologie |
US20060167106A1 (en) * | 2004-11-19 | 2006-07-27 | Mei Zhang | Compounds acting at the centrosome |
US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
KR20070121669A (ko) * | 2005-02-16 | 2007-12-27 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 뼈 상태 치료 또는 예방을 위한 약제학적 조성물 |
BRPI0618468A2 (pt) * | 2005-11-09 | 2011-08-30 | Proteolix Inc | compostos para inibição de enzima |
WO2007149512A2 (en) | 2006-06-19 | 2007-12-27 | Proteolix, Inc. | Peptide epoxyketones for pr0teas0me inhibition |
JP5384120B2 (ja) * | 2007-02-16 | 2014-01-08 | アンジェスMg株式会社 | 歯周病、及び外科手術による歯槽骨欠損の治療剤 |
US7781650B2 (en) * | 2007-04-30 | 2010-08-24 | Monsanto Technology Llc | Plants and seeds of corn variety CV202909 |
MY166950A (en) * | 2007-10-04 | 2018-07-25 | Onyx Therapeutics Inc | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
EP3090737A1 (en) | 2008-10-21 | 2016-11-09 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
AU2010341530B2 (en) | 2009-12-22 | 2016-03-10 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
MX2012011604A (es) | 2010-04-07 | 2013-02-27 | Onyx Therapeutics Inc | Inhibidor de inmunoproteasoma de péptido epoxicetona cristalino. |
CA2798517C (en) | 2010-05-17 | 2016-07-05 | The Procter & Gamble Company | Systems and methods of detecting and demonstrating hair damage via evaluation of protein fragments |
JP5737756B2 (ja) * | 2011-07-06 | 2015-06-17 | Necプラットフォームズ株式会社 | 通信装置およびパケット廃棄軽減方法 |
WO2013167927A1 (en) * | 2012-05-11 | 2013-11-14 | Biologix Hair Science Ltd. | Formulation and method for treating hair loss |
TW201414751A (zh) | 2012-07-09 | 2014-04-16 | 歐尼克斯治療公司 | 肽環氧酮蛋白酶抑制劑之前驅藥物 |
US20150209281A1 (en) * | 2012-07-18 | 2015-07-30 | Onyx Therapeutics, Inc. | Liposomal compositions of epoxyketone-based proteasome inhibitors |
SG10201913448UA (en) * | 2013-03-15 | 2020-02-27 | Human Biomolecular Res Institute | Compounds and matrices for use in bone growth and repair |
CN111514128A (zh) * | 2020-04-30 | 2020-08-11 | 广州中医药大学第一附属医院 | 羟基红花黄色素a在制备治疗骨质疏松药物中的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761471A (en) | 1980-08-04 | 1988-08-02 | The Regents Of The University Of California | Bone morphogenetic protein composition |
JPS60243008A (ja) * | 1984-05-17 | 1985-12-03 | Wakamoto Pharmaceut Co Ltd | 発毛養毛剤 |
JPS6219513A (ja) * | 1985-07-17 | 1987-01-28 | Shiseido Co Ltd | 養毛剤 |
ATE162223T1 (de) | 1989-03-28 | 1998-01-15 | Genetics Inst | Osteoinduktive zusammensetzungen |
ES2074724T3 (es) | 1990-08-14 | 1995-09-16 | Howmedica | Estimulador del crecimiento oseo. |
JPH0597697A (ja) | 1991-10-02 | 1993-04-20 | Lion Corp | 歯槽骨再生剤 |
WO1993020859A1 (en) | 1992-04-20 | 1993-10-28 | Board Of Regents Of The University Of Washington | Sustained release compositions for delivery of growth factors |
EP0672151A1 (en) * | 1992-06-12 | 1995-09-20 | Massachusetts Institute Of Technology | Inhibitors of ced-3 and related proteins |
US5962301A (en) * | 1992-06-12 | 1999-10-05 | Massachusetts Institute Of Technology | Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor |
US5280040A (en) | 1993-03-11 | 1994-01-18 | Zymogenetics, Inc. | Methods for reducing bone loss using centchroman derivatives |
US5965530A (en) | 1993-03-26 | 1999-10-12 | Amgen Inc. | Therapeutic uses of keratinocyte growth factor |
US5840277A (en) | 1993-03-30 | 1998-11-24 | Charlotte Hospital Authority | Treatment of chronic pulmonary inflammation |
UA44257C2 (uk) | 1993-10-21 | 2002-02-15 | Мерк Енд Ко, Інк | 16-ЗАМІЩЕНІ ПОХІДНІ 4-АЗААНДРОСТАНУ, ЯК ІНГІБІТОРИ ІЗОФЕРМЕНТУ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, СПОСІБ ІНГІБУВАННЯ 5-<font face="Symbol">a</font>-РЕДУКТАЗИ ТА ЇЇ ІЗОФЕРМЕНТУ, СПОСІБ ЛІКУВАННЯ, СПОСІБ ПРИПИНЕННЯ ТА ОБЕРНЕННЯ АНДРОГЕННОЇ АЛОПЕЦІЇ ТА СТИМУЛЮВАННЯ РОСТУ ВОЛОССЯ У ССАВЦІВ, СПОСІБ ІНГІБУВАННЯ БІОСИНТЕТИЧНОЇ КОНВЕРСІЇ ТЕСТОСТЕРОНУ В ДИГІДРОТЕСТОСТЕРОН У ССАВЦІВ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ |
US5580854A (en) | 1994-03-04 | 1996-12-03 | Mount Sinai School Of Medicine Of The City University Of New York | Substrate-related peptidyl-aldehyde inhibitors of the proteolytic activity of the multicatalytic proteinase complex |
JPH09510209A (ja) | 1994-03-08 | 1997-10-14 | オステオサ インコーポレイテッド | 骨の成長を刺激するための繊維芽細胞成長因子の用途 |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) * | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
WO1996033268A1 (en) * | 1995-04-21 | 1996-10-24 | Merck & Co., Inc. | Apopain |
US5767152A (en) | 1995-05-04 | 1998-06-16 | Nielsen; Thor Bagger | Composition and methods for stimulating hair growth |
US6083690A (en) | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
US5728844A (en) | 1995-08-29 | 1998-03-17 | Celgene Corporation | Immunotherapeutic agents |
WO1997009315A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
BR9611210A (pt) | 1995-10-23 | 1999-12-28 | Zymogenetics Inc | Composições e processos para tratamento de condições ósseas deficitárias |
FR2741076B1 (fr) * | 1995-11-15 | 1998-01-30 | Rech De Pathologie Appliquee S | Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant |
BR9711805A (pt) | 1996-06-20 | 2002-01-15 | Regents The Univesity Of Texas | Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos |
JP2001510450A (ja) | 1996-10-23 | 2001-07-31 | ザイモジェネティクス,インコーポレイテッド | 骨欠損状態を処置するための組成物および方法 |
CA2274789A1 (en) | 1996-12-13 | 1998-06-18 | Zymogenetics, Inc. | Compositions and methods for stimulating bone growth |
US6495532B1 (en) * | 1997-03-19 | 2002-12-17 | Sky High, Llc | Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof |
DE19716713A1 (de) | 1997-04-21 | 1998-10-22 | Paz Arzneimittelentwicklung | Arzneimittel, enthaltend Ibuprofenthioester als Hemmer der Nf-kappaB abhängigen Bildung von Mediatoren von Entzündung und Schmerz |
JPH11180873A (ja) | 1997-12-22 | 1999-07-06 | Kaken Shoyaku Kk | NF−κB活性阻害剤 |
US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
US6462019B1 (en) * | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6902721B1 (en) * | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6492333B1 (en) * | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
-
1998
- 1998-07-10 US US09/113,947 patent/US6462019B1/en not_active Expired - Lifetime
-
1999
- 1999-07-09 EP EP99933827A patent/EP1096924B1/en not_active Expired - Lifetime
- 1999-07-09 JP JP2000558808A patent/JP2003522107A/ja not_active Withdrawn
- 1999-07-09 DK DK99933827T patent/DK1096924T3/da active
- 1999-07-09 CA CA2337988A patent/CA2337988C/en not_active Expired - Fee Related
- 1999-07-09 PT PT99933827T patent/PT1096924E/pt unknown
- 1999-07-09 DE DE69934120T patent/DE69934120T2/de not_active Expired - Lifetime
- 1999-07-09 ES ES99933827T patent/ES2273505T3/es not_active Expired - Lifetime
- 1999-07-09 AT AT99933827T patent/ATE345785T1/de active
- 1999-07-09 AU AU63109/99A patent/AU771297B2/en not_active Ceased
- 1999-07-09 WO PCT/US1999/015533 patent/WO2000002548A2/en active IP Right Grant
- 1999-07-27 US US09/361,775 patent/US6410512B1/en not_active Expired - Fee Related
-
2001
- 2001-09-19 HK HK01106606A patent/HK1035870A1/xx not_active IP Right Cessation
-
2002
- 2002-01-15 US US10/050,425 patent/US6958220B2/en not_active Expired - Fee Related
-
2005
- 2005-11-15 JP JP2005330878A patent/JP4469780B2/ja not_active Expired - Lifetime
-
2007
- 2007-02-09 CY CY20071100174T patent/CY1107323T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE69934120D1 (de) | 2007-01-04 |
PT1096924E (pt) | 2007-02-28 |
JP4469780B2 (ja) | 2010-05-26 |
EP1096924B1 (en) | 2006-11-22 |
HK1035870A1 (en) | 2001-12-14 |
JP2003522107A (ja) | 2003-07-22 |
DE69934120T2 (de) | 2007-10-11 |
US6462019B1 (en) | 2002-10-08 |
WO2000002548A2 (en) | 2000-01-20 |
US6958220B2 (en) | 2005-10-25 |
ATE345785T1 (de) | 2006-12-15 |
CA2337988A1 (en) | 2000-01-20 |
CA2337988C (en) | 2011-04-26 |
AU771297B2 (en) | 2004-03-18 |
WO2000002548A3 (en) | 2003-04-17 |
DK1096924T3 (da) | 2007-03-26 |
JP2006089498A (ja) | 2006-04-06 |
US6410512B1 (en) | 2002-06-25 |
US20020103127A1 (en) | 2002-08-01 |
AU6310999A (en) | 2000-02-01 |
EP1096924A1 (en) | 2001-05-09 |
ES2273505T3 (es) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1107323T1 (el) | Αναστολεις πρωτεασωμικης δρασης για διεγepση τριχοφυϊας | |
EP1021179A4 (en) | METHOD FOR PROMOTING HAIR GROWTH AND DEVELOPING THE HAIR SYSTEM | |
HK1064315A1 (en) | Device stimulating the activity of hair follicles | |
DE3280344D1 (de) | Verwendung von retinoiden und minoxidil (2,4-diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia. | |
CY1108778T1 (el) | Μεθοδος αντιμετωπισης καρκινου του δερματος, χρησιμοποιωντας συνθεσεις οι οποιες περιλαμβανουν εναν αναστολεα του υποδοχεα ενδοθηλινης β | |
CY1111912T1 (el) | Μεθοδος αναστολης της δραστηριοτητας των οστεοκλαστων | |
ATE56862T1 (de) | Hautbehandlungszusammensetzung. | |
DK1290145T3 (da) | Tredimensional hudmodel | |
ATE258796T1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
BR9507112A (pt) | Preparações higiênicas e cosméticas para evitar e tratar doenças de pele processo para obtenção das mesmas e uso de água esgotada de deutério | |
DE3376524D1 (en) | Skin treatment composition | |
ATE514771T1 (de) | Haartransplantation | |
DE60015516D1 (de) | Verwendung von makroliden zur behandlung von trockenen augen | |
DE69621243T2 (de) | Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls | |
NZ506681A (en) | Disinfecting composition | |
ATE218862T1 (de) | Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen | |
ES2137125A1 (es) | La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. | |
ID24060A (id) | Pengolahan kulit hewan yang ditingkatkan | |
TW200716979A (en) | Screening methods for compounds that affect melanogenesis | |
DK1115375T3 (da) | Anvendelse af mindst ét 10-hydroxy-2-decensyrederivat i et præparat til at fremme hudafstödning | |
HUP9900007A2 (hu) | Készítmény baromfialom kezelésére | |
DE69820911D1 (de) | Verwendung einer Verbindung zur Herstellung eines Medikaments zur Behandlung von Alopecia oder zur Förderung des Haarwuchses bei Tieren | |
ATE358490T1 (de) | Verwendung einer kombination aus einem purin und einem no-donor zur behandlung und prophylaxe sexueller funktionsstörungen | |
ES2152187A1 (es) | Locion estimulante del foliculo piloso. | |
ATE64525T1 (de) | Verwendung von retinoiden und minoxidil (2,4diamino-6-piperidino-pyrimidine-3-oxid) zur verbesserung des wachstums von menschlichem kopfhaar und zur behandlung bestimmter typen von alopecia. |